Aimmune Therapeutics (Aimmune Therapeutics) Days Sales Outstanding : 0.00 (As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aimmune Therapeutics Days Sales Outstanding?

Aimmune Therapeutics's average Accounts Receivable for the three months ended in Jun. 2020 was $0.40 Mil. Aimmune Therapeutics's Revenue for the three months ended in Jun. 2020 was $0.00 Mil.

The historical rank and industry rank for Aimmune Therapeutics's Days Sales Outstanding or its related term are showing as below:

AIMT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0 Med: 0 Max: 252.96
Current: 252.96

During the past 7 years, Aimmune Therapeutics's highest Days Sales Outstanding was 252.96. The lowest was 0.00. And the median was 0.00.

AIMT's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.38 vs AIMT: 252.96

Aimmune Therapeutics's Days Sales Outstanding stayed the same from Jun. 2019 (0.00) to Jun. 2020 (0.00).

Aimmune Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Aimmune Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aimmune Therapeutics Days Sales Outstanding Chart

Aimmune Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Days Sales Outstanding

Get a 7-Day Free Trial

Aimmune Therapeutics Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	122.51	-

Competitive Comparison of Aimmune Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Aimmune Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aimmune Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aimmune Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Aimmune Therapeutics's Days Sales Outstanding falls into.

Aimmune Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Aimmune Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2019 is calculated as

	Days Sales Outstanding (A: Dec. 2019 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2018 )	+	Accounts Receivable (A: Dec. 2019 ))	/	count )	/	Revenue (A: Dec. 2019 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Aimmune Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2020 is calculated as:

	Days Sales Outstanding (Q: Jun. 2020 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2020 )	+	Accounts Receivable (A: Jun. 2020 ))	/	count )	/	Revenue (A: Jun. 2020 )	*	Days in Period
=	( (0.772	+	0.025)	/	2 )	/	0	*	365 / 4
=	0.3985					/	0	*	365 / 4
=	N/A

Aimmune Therapeutics (NAS:AIMT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Aimmune Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Aimmune Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Aimmune Therapeutics (Aimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aimmune Therapeutics Inc (NAS:AIMT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 300, Brisbane, CA, USA, 94005

Website

https://www.aimmune.com

Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Executives

Gregory Behar	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Societe Des Produits Nestle S.a.	10 percent owner	AVENUE NESTLE 55, VEVEY V8 CH-1800
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Andrew Oxtoby	officer: Chief Commercial Officer	8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Dallas Jayson Donald Alexander	director, officer: President and CEO	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Brett K Haumann	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Douglas T. Sheehy	officer: See Remarks	C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005-1884
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Patrick G Enright	director	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Adelman Daniel C Md	officer: Chief Medical Officer	23 WOODLEAF AVENUE, REDWOOD CITY CA 94061
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Sa Nestle	10 percent owner	AVE NESTLE 55, CH-1800, VEVEY V8
Mary M. Rozenman	officer: See Remarks	AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005